Erythropoietic Agents and the Elderly

Seminars in Hematology

Volumn 45, Issue 4, 2008, Pages 267-275

  Agarwal, Neeraj ^a   Prchal, Josef T ^a  

^a UNIVERSITY OF UTAH SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIANEMIC AGENT; CNTO 530; CONTINUOUS ERYTHROPOIESIS RECEPTOR ACTIVATOR; ERYTHROPOIETIC AGENT; ERYTHROPOIETIN; ERYTHROPOIETIN MIMETIC PEPTIDE 1; ERYTHROPOIETIN RECEPTOR; FG 2216; FG 4539; FG 4592; HYPOXIA INDUCIBLE FACTOR 1ALPHA; HYPOXIA INDUCIBLE FACTOR 2ALPHA; K 11706; MIRCERA; NOVEL ERYTHROPOIESIS STIMULATING PROTEIN; PLACEBO; PROLINE HYDROXYLASE INHIBITOR; RECOMBINANT ERYTHROPOIETIN; UNCLASSIFIED DRUG; ZIDOVUDINE;

ABSENCE OF SIDE EFFECTS; AGED; ALTITUDE; ANEMIA; ARTICLE; BRAIN INFARCTION SIZE; BRAIN INJURY; CANCER PATIENT; CELL REGENERATION; CLINICAL TRIAL; CONGESTIVE HEART FAILURE; CRITICALLY ILL PATIENT; DRUG BLOOD LEVEL; DRUG DOSE ESCALATION; DRUG EFFICACY; DRUG HALF LIFE; GERIATRIC CARE; HEALTH CARE; HEALTH CARE COST; HEART FUNCTION; HEART INFARCTION SIZE; HUMAN; HYPOXIA; ISCHEMIC HEART DISEASE; KIDNEY FUNCTION; MORBIDITY; MORTALITY; NEOPLASM; NERVE CELL; NEUROPROTECTION; NONHUMAN; PHYSICAL ACTIVITY; PREVALENCE; PRIORITY JOURNAL; QUALITY OF LIFE; RECOMMENDED DRUG DOSE; STROKE; THROMBOEMBOLISM; TREATMENT OUTCOME; UNEXPLAINED ANEMIA;

AGED; ANEMIA; ANIMALS; CRITICAL ILLNESS; ERYTHROPOIESIS; ERYTHROPOIETIN; ERYTHROPOIETIN, RECOMBINANT; HEMATINICS; HUMANS; KIDNEY FAILURE, CHRONIC; MICE; PEPTIDES; PEPTIDES, CYCLIC; POLYETHYLENE GLYCOLS; RECEPTORS, ERYTHROPOIETIN;

EID: 52049124252     PISSN: 00371963     EISSN: None     Source Type: Journal    
DOI: 10.1053/j.seminhematol.2008.06.007     Document Type: Article

References (107)

1. Koury S.T., Bondurant M.C., and Koury M.J. Localization of erythropoietin synthesizing cells in murine kidneys by in situ hybridization. Blood 71 (1988) 524-527
2. Koury S.T., Bondurant M.C., Koury M.J., and Semenza G.L. Localization of cells producing erythropoietin in murine liver by in situ hybridization. Blood 77 (1991) 2497-2503
3. D'Andrea A.D., Lodish H.F., and Wong G.G. Expression cloning of the murine erythropoietin receptor. Cell 57 (1989) 277-285
4. Koury M.J., and Bondurant M.C. Erythropoietin retards DNA breakdown and prevents programmed death in erythroid progenitor cells. Science 248 (1990) 378-381
5. Kelley L.L., Koury M.J., Bondurant M.C., Koury S.T., Sawyer S.T., and Wickrema A. Survival or death of individual proerythroblasts results from differing erythropoietin sensitivities: a mechanism for controlled rates of erythrocyte production. Blood 82 (1993) 2340-2352
6. Lin C.S., Lim S.K., D'Agati V., and Costantini F. Differential effects of an erythropoietin receptor gene disruption on primitive and definitive erythropoiesis. Genes Dev 10 (1996) 154-164
7. Rice L., and Alfrey C.P. The negative regulation of red cell mass by neocytolysis: physiologic and pathophysiologic manifestations. Cell Physiol Biochem 15 (2005) 245-250
8. Anagnostou A., Lee E.S., Kessimian N., Levinson R., and Steiner M. Erythropoietin has a mitogenic and positive chemotactic effect on endothelial cells. Proc Natl Acad Sci U S A 87 (1990) 5978-5982
9. Fraser J.K., Tan A.S., Lin F.K., and Berridge M.V. Expression of specific high-affinity binding sites for erythropoietin on rat and mouse megakaryocytes. Exp Hematol 17 (1989) 10-16
10. Nagai A., Nakagawa E., Choi H.B., Hatori K., Kobayashi S., and Kim S.U. Erythropoietin and erythropoietin receptors in human CNS neurons, astrocytes, microglia, and oligodendrocytes grown in culture. J Neuropathol Exp Neurol 60 (2001) 386-392
11. Wu H., Lee S.H., Gao J., Liu X., and Iruela-Arispe M.L. Inactivation of erythropoietin leads to defects in cardiac morphogenesis. Development 126 16 (1999) 3597-3605
12. Yasuda Y., Masuda S., Chikuma M., Inoue K., Nagao M., and Sasaki R. Estrogen-dependent production of erythropoietin in uterus and its implication in uterine angiogenesis. J Biol Chem 273 (1998) 25381-25387
13. Juul S.E., Zhao Y., Dame J.B., Du Y., Hutson A.D., and Christensen R.D. Origin and fate of erythropoietin in human milk. Pediatr Res 48 (2000) 660-667
14. Magnanti M., Gandini O., Giuliani L., Gazzaniga P., Marti H.H., Gradilone A., et al. Erythropoietin expression in primary rat Sertoli and peritubular myoid cells. Blood 98 (2001) 2872-2874
15. Brines M., and Cerami A. Discovering erythropoietin's extra-hematopoietic functions: biology and clinical promise. Kidney Int 70 (2006) 246-250
16. Agarwal N., Gordeuk V.R., and Prchal J.T. Are erythropoietin receptors expressed in tumors?. Facts and fiction-More careful studies are needed. J Clin Oncol 25 (2007) 1813-1814
17. Yoon D., Agarwal N., and Prchal J.T. Does erythropoietin promote tumor growth?. Clin Cancer Res 14 (2008) 1920
18. Hardee M.E., Cao Y., Fu P., Jiang X., Zhao Y., Rabbani Z.N., et al. Erythropoietin blockade inhibits the induction of tumor angiogenesis and progression. PLoS ONE 2 (2007) e549
19. Arcasoy M.O. The non-haematopoietic biological effects of erythropoietin. Br J Haematol 141 (2008) 14-31
20. Wang G.L., Jiang B.H., Rue E.A., and Semenza G.L. Hypoxia-inducible factor 1 is a basic-helix-loop-helix-PAS heterodimer regulated by cellular O2 tension. Proc Natl Acad Sci U S A 92 (1995) 5510-5514
21. Ang S.O., Chen H., Hirota K., Gordeuk V.R., Jelinek J., Guan Y., et al. Disruption of oxygen homeostasis underlies congenital Chuvash polycythemia. Nature Genet 32 (2002) 614-621
22. Semenza G. HIF-1 and mechanisms of hypoxia sensing. Curr Opin Cell Biol 13 (2001) 167-171
23. Maxwell P.H., Wiesener M.S., Chang G.W., Clifford S.C., Vaux E.C., Cockman M.E., et al. The tumour suppressor protein VHL targets hypoxia-inducible factors for oxygen-dependent proteolysis. Nature 399 (1999) 271-275
24. 2 sensing. Science 292 (2001) 464-468
25. 2-regulated prolyl hydroxylation. Science 292 (2001) 468-472
26. Gordeuk V., Sergueeva A.I., Miasnikova G.Y., Okhotin D., Voloshin Y., Choyke P.L., et al. Congenital disorder of oxygen sensing: Association of the homozygous Chuvash polycythemia VHL mutation with thrombosis and vascular abnormalities but not tumors. Blood 103 (2004) 3924-3932
27. Iwai K., Yamanaka K., Kamura T., Minato N., Conaway R.C., Conaway J.W., et al. Identification of the von Hippel-lindau tumor-suppressor protein as part of an active E3 ubiquitin ligase complex. Proc Natl Acad Sci U S A 96 (1999) 12436-12441
28. Hirota K., and Semenza G.L. Regulation of angiogenesis by hypoxia-inducible factor 1. Crit Rev Oncol Hematol 59 (2006) 15-26
29. Gruber M., Hu C.J., Johnson R.S., Brown E.J., Keith B., and Simon M.C. Acute postnatal ablation of Hif-2alpha results in anemia. Proc Natl Acad Sci U S A 104 (2007) 2301-2306
30. Chavez J.C., Baranova O., Lin J., and Pichiule P. The transcriptional activator hypoxia inducible factor 2 (HIF-2/EPAS-1) regulates the oxygen-dependent expression of erythropoietin in cortical astrocytes. J Neurosci 26 (2006) 9471-9481
31. Rankin E.B., Biju M.P., Liu Q., Unger T.L., Rha J., Johnson R.S., et al. Hypoxia-inducible factor-2 (HIF-2) regulates hepatic erythropoietin in vivo. J Clin Invest 117 (2007) 1068-1077
32. Sanchez M., Galy B., Muckenthaler M.U., and Hentze M.W. Iron-regulatory proteins limit hypoxia-inducible factor-2alpha expression in iron deficiency. Nat Struct Mol Biol 14 (2007) 420-426
33. Percy M.J., Furlow P.W., Lucas G.S., Li X., Lappin T.R., McMullin M.F., et al. A gain-of-function mutation in the HIF2A gene in familial erythrocytosis. N Engl J Med 358 (2008) 162-168
34. Carbia-Nagashima A., Gerez J., Perez-Castro C., Paez-Pereda M., Silberstein S., Stalla G.K., et al. RSUME, a small RWD-containing protein, enhances SUMO conjugation and stabilizes HIF-1alpha during hypoxia. Cell 131 (2007) 309-323
35. Liu Y.V., Hubbi M.E., Pan F., McDonald K.R., Mansharamani M., Cole R.N., et al. Calcineurin promotes hypoxia-inducible factor 1alpha expression by dephosphorylating RACK1 and blocking RACK1 dimerization. J Biol Chem 282 (2007) 37064-37073
36. Skibeli V., Nissen-Lie G., and Torjesen P. Sugar profiling proves that human serum erythropoietin differs from recombinant human erythropoietin. Blood 98 (2001) 3626-3634
37. Goldwasser E., Kung C.K., and Eliason J. On the mechanism of erythropoietin-induced differentiation. 13. The role of sialic acid in erythropoietin action. J Biol Chem 249 (1974) 4202-4206
38. Egrie J.C., Dwyer E., Browne J.K., Hitz A., and Lykos M.A. Darbepoetin alfa has a longer circulating half-life and greater in vivo potency than recombinant human erythropoietin. Experimental Hematol 31 (2003) 290-299
39. Beutel G., and Ganser A. Risks and benefits of erythropoiesis-stimulating agents in cancer management. Semin Hematol 44 (2007) 157-165
40. FDA, and USFaDA. http://www.fda.gov/bbs/topics/NEWS/2007/ NEW01740.html Accessed April 5, 2008
41. FDA, and USFaDA. http://www.fda.gov/medwatch/safety/2007/safety07.htm#ESA Drugs and Therapeutic Biological Products (CDER). Accessed April 6, 2008
42. Procrit (epoetin alfa) full prescribing information. http://www.procrit.com/procrit/shared/OBI/PI/ProcritBooklet.pdf#page=1 Accessed April 6, 2008
43. Reocormon (Epoetin beta) full prescribing information. http://www.medsafe.govt.nz/profs/Datasheet/r/Recormoninj.htm Accessed April 6, 2008
44. Aranesp (darbepoetin alpha) full prescribing information. http://www.aranesp.com/ Accessed April 6, 2008
45. Kwan J.T., and Pratt R.D. Epoetin delta, erythropoietin produced in a human cell line, in the management of anaemia in predialysis chronic kidney disease patients. Curr Med Res Opin 23 (2007) 307-311
46. Martin K.J. The first human cell line-derived erythropoietin, epoetin-delta (Dynepo), in the management of anemia in patients with chronic kidney disease. Clin Nephrol 68 (2007) 26-31
47. Macdougall I.C. CERA (continuous erythropoietin receptor activator): A new erythropoiesis-stimulating agent for the treatment of anemia. Curr Hematol Rep 4 (2005) 436-440
48. Fishbane S., Pannier A., Liogier X., Jordan P., Dougherty F.C., and Reigner B. Pharmacokinetic and pharmacodynamic properties of methoxy polyethylene glycol-epoetin beta are unaffected by the site of subcutaneous administration. J Clin Pharmacol 47 (2007) 1390-1397
49. Hirsh V., Glaspy J., Mainwaring P., Manegold C., Ramlau R., and Eid J.E. Phase II study of two dose schedules of C.E.R.A. (continuous erythropoietin receptor activator) in anemic patients with advanced non-small cell lung cancer (NSCLC) receiving chemotherapy. Trials 8 (2007) 8
50. Sulowicz W., Locatelli F., Ryckelynck J.P., Balla J., Csiky B., Harris K., et al. Once-monthly subcutaneous C.E.R.A. maintains stable hemoglobin control in patients with chronic kidney disease on dialysis and converted directly from epoetin one to three times weekly. Clin J Am Soc Nephrol 2 (2007) 637-646
51. Levin N.W., Fishbane S., Canedo F.V., Zeig S., Nassar G.M., Moran J.E., et al. Intravenous methoxy polyethylene glycol-epoetin beta for haemoglobin control in patients with chronic kidney disease who are on dialysis: A randomised non-inferiority trial (MAXIMA). Lancet 370 (2007) 1415-1421
52. Hsieh M.M., Linde N.S., Wynter A., Metzger M., Wong C., Langsetmo I., et al. HIF prolyl hydroxylase inhibition results in endogenous erythropoietin induction, erythrocytosis, and modest fetal hemoglobin expression in rhesus macaques. Blood 110 (2007) 2140-2147
53. Bernhardt W., Wiesener M.S., Schmieder R.E., Gunzler V., Eckardt K.U., et al. The prolyl hydroxylase inhibitor FG-2216 stimulates EPO production in nephric and anephric dialysis patients-Evidence for an underutilized production capacity in liver and kidneys. American Society of Nephrology Renal Week (2007) San Francisco, CA, November 2-5, (abstr SA-PO784)
54. Frohna P., Milwee S., Pinkett J., Lee T., Moore-Perry K., Chou J., et al. Results from a randomized, single-blind, placebo-controlled trial of FG-4592, a novel hypoxia inducible factor prolyl hydroxylase inhibitor, in CKD anemia. American Society of Nephrology Renal Week (2007) San Francisco, CA, November 2-5, (abstr SU-PO806)
55. Johnson D.L., Farrell F.X., Barbone F.P., McMahon F.J., Tullai J., Hoey K., et al. Identification of a 13 amino acid peptide mimetic of erythropoietin and description of amino acids critical for the mimetic activity of EMP1. Biochemistry 37 (1998) 3699-3710
56. Macdougall I.C. Novel erythropoiesis-stimulating agents: A new era in anemia management. Clin J Am Soc Nephrol 3 (2008) 200-207
57. Fan Q., Leuther K.K., Holmes C.P., Fong K.L., Zhang J., Velkovska S., et al. Preclinical evaluation of Hematide, a novel erythropoiesis stimulating agent, for the treatment of anemia. Exp Hematol 34 (2006) 1303-1311
58. Stead R.B., Lambert J., Wessels D., Iwashita J.S., Leuther K.K., Woodburn K.W., et al. Evaluation of the safety and pharmacodynamics of Hematide, a novel erythropoietic agent, in a phase 1, double-blind, placebo-controlled, dose-escalation study in healthy volunteers. Blood 108 (2006) 1830-1834
59. Macdougall I., Tucker B., Yaqoob M., Mikhail A., Nowicki M., MacPhee I., et al. Hematide, a synthetic peptide-based erythropoiesis stimulating agent, achieves correction of anemia and maintains hemoglobin in patients with chronic kidney disease not on dialysis. Annual meeting of the American Society of Nephrology, San Diego, CA (2006) November 14-19, (abstr F-FC079)
60. Besarab A., Zeig S., Geronemus R., Pergola P., Whittier F., Zabaneh R., et al. Hematide, a synthetic peptide-based erythropoiesis stimulating agent, maintains hemoglobin in hemodialysis patients previously treated epoetin alfa. National Kidney Foundation Spring Clinical Meeting, Orlando, FL (2007) April 10-14, (abstr 99)
61. Pickering L., Cwiertka K., Jassem J., Petera J., Pettengell R., Ramlau R., et al. Correction of anemia with Hematide, a synthetic peptide-based erythropoiesis stimulating agent (ESA), in oncology patients receiving chemotherapy. Blood 110 (2007) (abstr 3666)
62. Woodburn K.W., Fan Q., Winslow S., Chen M.J., Mortensen R.B., Casadevall N., et al. Hematide is immunologically distinct from erythropoietin and corrects anemia induced by antierythropoietin antibodies in a rat pure red cell aplasia model. Exp Hematol 35 (2007) 1201-1208
63. Bugelski P.J., Capocasale R.J., Makropoulos D., Marshall D., Fisher P.W., Lu J., et al. CNTO 530: Molecular pharmacology in human UT-7(EPO) cells and pharmacokinetics and pharmacodynamics in mice. J Biotechnol 134 (2008) 171-180
64. Nakano Y., Imagawa S., Matsumoto K., Stockmann C., Obara N., Suzuki N., et al. Oral administration of K-11706 inhibits GATA binding activity, enhances hypoxia-inducible factor 1 binding activity, and restores indicators in an in vivo mouse model of anemia of chronic disease. Blood 104 (2004) 4300-4307
65. Spencer D.M., Wandless T.J., Schreiber S.L., and Crabtree G.R. Controlling signal transduction with synthetic ligands. Science 262 (1993) 1019-1024
66. Neff T., and Blau C.A. Pharmacologically regulated cell therapy. Blood 97 (2001) 2535-2540
67. Weinreich M.A., Lintmaer I., Wang L., Liggitt H.D., Harkey M.A., and Blau C.A. Growth factor receptors as regulators of hematopoiesis. Blood 108 (2006) 3713-3721
68. Neff T., Horn P.A., Valli V.E., Gown A.M., Wardwell S., Wood B.L., et al. Pharmacologically regulated in vivo selection in a large animal. Blood 100 (2002) 2026-2031
69. Nagasawa Y., Wood B.L., Wang L., Lintmaer I., Guo W., Papayannopoulou T., et al. Anatomical compartments modify the response of human hematopoietic cells to a mitogenic signal. Stem Cells 24 (2006) 908-917
70. Chen Z.Y., Asavaritikrai P., Prchal J.T., and Noguchi C.T. Endogenous erythropoietin signaling is required for normal neural progenitor cell proliferation. J BiolChem 282 (2007) 25875-25883
71. Brines M., Grasso G., Fiordaliso F., Sfacteria A., Ghezzi P., Fratelli M., et al. Erythropoietin mediates tissue protection through an erythropoietin and common beta-subunit heteroreceptor. Proc Natl Acad Sci U S A 101 (2004) 14907-14912
72. Digicaylioglu M., and Lipton S.A. Erythropoietin-mediated neuroprotection involves cross-talk between Jak2 and NF-kappaB signalling cascades. Nature 412 (2001) 641-647
73. Genc S., Koroglu T.F., and Genc K. Erythropoietin and the nervous system. Brain Res 1000 (2004) 19-31
74. Lee S.T., Chu K., Sinn D.I., Jung K.H., Kim E.H., Kim S.J., et al. Erythropoietin reduces perihematomal inflammation and cell death with eNOS and STAT3 activations in experimental intracerebral hemorrhage. J Neurochem 96 (2006) 1728-1739
75. Bianchi R., Buyukakilli B., Brines M., Savino C., Cavaletti G., Oggioni N., et al. Erythropoietin both protects from and reverses experimental diabetic neuropathy. Proc Natl Acad Sci U S A 101 (2004) 823-828
76. Watanabe D., Suzuma K., Matsui S., Kurimoto M., Kiryu J., Kita M., et al. Erythropoietin as a retinal angiogenic factor in proliferative diabetic retinopathy. N Engl J Med 353 (2005) 782-792
77. Ehrenreich H., Hasselblatt M., Dembowski C., Cepek L., Lewczuk P., Stiefel M., et al. Erythropoietin therapy for acute stroke is both safe and beneficial. Mol Med 8 (2002) 495-505
78. Ehrenreich H., Fischer B., Norra C., Schellenberger F., Stender N., Stiefel M., et al. Exploring recombinant human erythropoietin in chronic progressive multiple sclerosis. Brain 130 (2007) 2577-2588
79. Blau C.A. Erythropoietin in cancer: Presumption of innocence?. Stem Cells 25 (2007) 2094-2097
80. Elliott S., Busse L., Bass M.B., Lu H., Sarosi I., Sinclair A.M., et al. Anti-Epo receptor antibodies do not predict Epo receptor expression. Blood 107 (2006) 1892-1895
81. Necas E., and Prchal J.T. The diverse functions of Lipocalin: A recently-recognized mediator of transferrin independent iron transport, innate immunity, and cancer signaling. Hematologist 3 (2006) 3
82. Whitnall M., Howard J., Ponka P., and Richardson D.R. A class of iron chelators with a wide spectrum of potent antitumor activity that overcomes resistance to chemotherapeutics. Proc Natl Acad Scie U S A 103 (2006) 14901-14906
83. Bennett C.L., Silver S.M., Djulbegovic B., Samaras A.T., Blau C.A., Gleason K.J., et al. Venous thromboembolism and mortality associated with recombinant erythropoietin and darbepoetin administration for the treatment of cancer-associated anemia. JAMA 299 (2008) 914-924
84. Kimel M., Leidy N.K., Mannix S., and Dixon J. Does epoetin alfa improve health-related quality of life in chronically ill patients with anemia?. Summary of trials of cancer, HIV/AIDS, and chronic kidney disease. Value Health 11 (2008) 57-75
85. Westenfelder C., Biddle D.L., and Baranowski R.L. Human, rat, and mouse kidney cells express functional erythropoietin receptors. Kidney Int 55 (1999) 808-820
86. Fliser D., and Haller H. Erythropoietin and treatment of non-anemic conditions-Cardiovascular protection. Semin Hematol 44 (2007) 212-217
87. Bahlmann F.H., Song R., Boehm S.M., Mengel M., von Wasielewski R., Lindschau C., et al. Low-dose therapy with the long-acting erythropoietin analogue darbepoetin alpha persistently activates endothelial Akt and attenuates progressive organ failure. Circulation 110 (2004) 1006-1012
88. Parsa C.J., Matsumoto A., Kim J., Riel R.U., Pascal L.S., Walton G.B., et al. A novel protective effect of erythropoietin in the infarcted heart. J Clin Invest 112 (2003) 999-1007
89. Westenbrink B.D., Lipsic E., van der Meer P., van der Harst P., Oeseburg H., Du Marchie Sarvaas G.J., et al. Erythropoietin improves cardiac function through endothelial progenitor cell and vascular endothelial growth factor mediated neovascularization. Eur Heart J 28 (2007) 2018-2027
90. Besarab A., Bolton W.K., Browne J.K., Egrie J.C., Nissenson A.R., Okamoto D.M., et al. The effects of normal as compared with low hematocrit values in patients with cardiac disease who are receiving hemodialysis and epoetin. N Engl J Med Aug 339 (1998) 584-590
91. Ghali J.K., Anand I.S., Abraham W.T., Fonarow G.C., Greenberg B., Krum H., et al. Randomized double-blind trial of darbepoetin alfa in patients with symptomatic heart failure and anemia. Circulation 117 (2008) 526-535
92. Prchal J.T., Semenza G.L., Prchal J., and Sokol L. Familial polycythemia. Science 268 (1995) 1831-1832
93. Gordeuk V.R., Sergueeva A.I., Miasnikova G.Y., Okhotin D., Voloshin Y., Choyke P.L., et al. Congenital disorder of oxygen sensing: association of the homozygous Chuvash polycythemia VHL mutation with thrombosis and vascular abnormalities but not tumors. Blood 103 (2004) 3924-3932
94. Bohlius J., Wilson J., Seidenfeld J., Piper M., Schwarzer G., Sandercock J., et al. Recombinant human erythropoietins and cancer patients: updated meta-analysis of 57 studies including 9353 patients. J Natl Cancer Inst 98 (2006) 708-714
95. Singh A.K., Szczech L., Tang K.L., Barnhart H., Sapp S., Wolfson M., et al. Correction of anemia with epoetin alfa in chronic kidney disease. N Engl J Med 355 (2006) 2085-2098
96. Corwin H.L., Gettinger A., Pearl R.G., Fink M.P., Levy M.M., Shapiro M.J., et al. Efficacy of recombinant human erythropoietin in critically ill patients: A randomized controlled trial. JAMA 288 (2002) 2827-2835
97. Corwin H.L., Gettinger A., Fabian T.C., May A., Pearl R.G., Heard S., et al. Efficacy and safety of epoetin alfa in critically ill patients. N Engl J Med 357 (2007) 965-976
98. Guralnik J.M., Eisenstaedt R.S., Ferrucci L., Klein H.G., and Woodman R.C. Prevalence of anemia in persons 65 years and older in the United States: Evidence for a high rate of unexplained anemia. Blood 104 (2004) 2263-2268
99. Guralnik J.M., Ershler W.B., Schrier S.L., and Picozzi V.J. Anemia in the elderly: A public health crisis in hematology. Hematology Education Program of the American Society of Hematology American Society of Hematology (2005) 528-532
100. Nilsson-Ehle H., Jagenburg R., Landahl S., and Svanborg A. Blood haemoglobin declines in the elderly: implications for reference intervals from age 70 to 88. Eur J Haematol 65 (2000) 297-305
101. Penninx B.W., Pahor M., Cesari M., Corsi A.M., Woodman R.C., Bandinelli S., et al. Anemia is associated with disability and decreased physical performance and muscle strength in the elderly. J Am Geriatr Soc 52 (2004) 719-724
102. Cesari M., Penninx B.W., Lauretani F., Russo C.R., Carter C., Bandinelli S., et al. Hemoglobin levels and skeletal muscle: Results from the InCHIANTI study. J Gerontol 59 (2004) 249-254
103. Lucca U., Tettamanti M., Mosconi P., Apolone G., Gandini F., Nobili A., et al. Association of mild anemia with cognitive, functional, mood and quality of life outcomes in the elderly: the "Health and Anemia" study. PLoS ONE 3 (2008) e1920
104. Denny S.D., Kuchibhatla M.N., and Cohen H.J. Impact of anemia on mortality, cognition, and function in community-dwelling elderly. Am J Med 119 (2006) 327-334
105. Semba R.D., Ricks M.O., Ferrucci L., Xue Q.L., Chaves P., Fried L.P., et al. Types of anemia and mortality among older disabled women living in the community: The Women's Health and Aging Study I. Aging Clin Exp Res 19 (2007) 259-264
106. Ershler W.B., Sheng S., McKelvey J., Artz A.S., Denduluri N., Tecson J., et al. Serum erythropoietin and aging: a longitudinal analysis. J Am Geriatr Soc 53 (2005) 1360-1365
107. Ershler W.B., Chen K., Reyes E.B., and Dubois R. Economic burden of patients with anemia in selected diseases. Value Health 8 (2005) 629-638